Sponsor:
UCLA
Code:
NCT05642858
Conditions
HIV
Human Immunodeficiency Virus
Cardiovascular Diseases
Atherosclerosis
Eligibility Criteria
Sex: All
Age: 40+
Healthy Volunteers: Not accepted
Interventions
Digital Educational Messaging
Brief summary:
Conditions
HIV
Human Immunodeficiency Virus
Cardiovascular Diseases
Atherosclerosis
Study ID
NCT05642858
Start date
Mar 12, 2023
Status verified date
Jun, 2025
Completion date
Jul 1, 2026
Anticipated
Primary completion date
Dec 1, 2025
Anticipated
Eligibility Criteria
Sex: All
Age: 40+
Healthy Volunteers: Not accepted
Enrollment
260 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Prevention
Arms
experimental: Intervention Arm
no intervention: Control Arm
Interventions
Digital Educational Messaging
Primary outcome measure
Central contacts
Locations
Zuckerberg San Francisco General Hospital
Recruiting
San Francisco, California, United States, 94110
Contacts
Megan McLaughlin, MD, MPH
teachhiv@ucsf.eduUniversity of California San Francisco
Recruiting
San Francisco, California, United States, 94115
Contacts
Megan Mclaughlin, MD, MPH
teachhiv@ucsf.eduSponsor
University of California, San Francisco
Last update posted
Jun 8, 2025
Last verified
Jun, 2025
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, San Francisco on 2025-06-08.